Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · February 29, 2024

Efficacy and Safety of Once Weekly Semaglutide 2.4 mg for Weight Management in East Asian Individuals With Overweight or Obesity

The Lancet Diabetes & Endocrinology


Additional Info

The Lancet Diabetes & Endocrinology
Efficacy and safety of once weekly semaglutide 2·4 mg for weight management in a predominantly east Asian population with overweight or obesity (STEP 7): a double-blind, multicentre, randomised controlled trial
Lancet Diabetes Endocrinol 2024 Feb 05;[EPub Ahead of Print], Y Mu, X Bao, FG Eliaschewitz, MR Hansen, BT Kim, A Koroleva, RCW Ma, T Yang, N Zu, M Liu

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading